$2.48 Billion is the total value of Avidity Partners Management LP's 83 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 54.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BSX | Buy | BOSTON SCIENTIFIC CORP | $109,074,240 | +156.7% | 2,065,800 | +162.9% | 4.39% | +196.0% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $103,228,400 | +18.5% | 797,500 | +13.5% | 4.16% | +36.6% |
| MCK | Buy | MCKESSON CORP | $72,315,555 | +67.2% | 166,300 | +64.3% | 2.91% | +92.8% |
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $64,953,390 | +17.8% | 967,000 | +21.0% | 2.62% | +35.8% |
| CI | New | THE CIGNA GROUP | $59,416,739 | – | 207,700 | +100.0% | 2.39% | – |
| UNH | New | UNITEDHEALTH GROUP INC | $56,570,118 | – | 112,200 | +100.0% | 2.28% | – |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $54,549,000 | +60.1% | 450,000 | +51.3% | 2.20% | +84.6% |
| HUM | New | HUMANA INC | $53,663,156 | – | 110,300 | +100.0% | 2.16% | – |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $50,271,650 | +14.8% | 715,000 | +30.0% | 2.02% | +32.3% |
| REGN | Buy | REGENERON PHARMACEUTICALS | $47,731,680 | +167.9% | 58,000 | +133.9% | 1.92% | +209.0% |
| ZTS | Buy | ZOETIS INCcl a | $45,600,158 | +22.0% | 262,100 | +20.8% | 1.84% | +40.7% |
| Buy | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $44,298,804 | +117.2% | 777,172 | +94.3% | 1.78% | +150.2% | |
| DHR | New | DANAHER CORPORATION | $43,814,460 | – | 176,600 | +100.0% | 1.76% | – |
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $41,729,299 | – | 801,100 | +100.0% | 1.68% | – |
| NTRA | Buy | NATERA INC | $39,780,750 | +88.8% | 899,000 | +107.7% | 1.60% | +117.7% |
| LNTH | Buy | LANTHEUS HLDGS INC | $38,797,632 | +88.6% | 558,400 | +127.8% | 1.56% | +117.5% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $37,745,352 | +43.9% | 751,600 | +81.1% | 1.52% | +65.9% |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $36,114,060 | – | 1,142,850 | +100.0% | 1.45% | – |
| PRVA | Buy | PRIVIA HEALTH GROUP INC | $35,537,300 | +26.0% | 1,545,100 | +43.1% | 1.43% | +45.3% |
| DXCM | New | DEXCOM INC | $35,239,410 | – | 377,700 | +100.0% | 1.42% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $32,526,420 | +23.5% | 1,587,429 | +19.7% | 1.31% | +42.4% |
| Buy | AMYLYX PHARMACEUTICALS INC | $32,169,571 | +65.5% | 1,756,940 | +94.9% | 1.30% | +90.7% | |
| Buy | CARIBOU BIOSCIENCES INC | $28,920,013 | +146.7% | 6,050,212 | +119.3% | 1.16% | +184.8% | |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $28,586,912 | -13.3% | 1,063,897 | +15.0% | 1.15% | -0.1% |
| HCA | New | HCA HEALTHCARE INC | $28,238,504 | – | 114,800 | +100.0% | 1.14% | – |
| New | NEUMORA THERAPEUTICS INC. | $25,398,000 | – | 1,800,000 | +100.0% | 1.02% | – | |
| Buy | STRUCTURE THERAPEUTICS INCsponsored ads | $25,210,000 | +1504.4% | 500,000 | +1222.8% | 1.02% | +1745.5% | |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $18,141,400 | – | 610,000 | +100.0% | 0.73% | – |
| Buy | AN2 THERAPEUTICS INC | $17,517,552 | +213.6% | 1,089,400 | +65.8% | 0.70% | +261.5% | |
| New | DIANTHUS THERAPEUTICS INC | $16,643,963 | – | 1,217,554 | +100.0% | 0.67% | – | |
| FUSN | Buy | FUSION PHARMACEUTICALS INC | $15,032,810 | -43.5% | 5,781,850 | +1.4% | 0.60% | -34.9% |
| CERE | Buy | CEREVEL THERAPEUTICS HLDNG I | $14,036,690 | -11.9% | 643,000 | +28.3% | 0.56% | +1.6% |
| TVTX | New | TRAVERE THERAPEUTICS INC | $11,827,620 | – | 1,323,000 | +100.0% | 0.48% | – |
| SDGR | Buy | SCHRODINGER INC | $11,279,730 | -17.8% | 399,000 | +45.1% | 0.45% | -5.2% |
| New | RAYZEBIO INC | $11,100,000 | – | 500,000 | +100.0% | 0.45% | – | |
| ACIU | Buy | AC IMMUNE SA | $8,463,930 | -1.3% | 2,969,800 | +2.3% | 0.34% | +13.7% |
| Buy | SYROS PHARMACEUTICALS INC | $6,245,511 | +35.4% | 1,581,142 | +8.0% | 0.25% | +56.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.